NewAmsterdam Pharma Company N.V.
NAMS
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.0B
$25.59
▲ +2.69%
P/E
-11.74
Mkt Cap
$3.0B
52-Wk Range
$23.05–$42.21
52-Week Range
$23.05 - $42.21
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 2.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Novel selective CETP inhibitor with dual lipid-modifying mechanism
- First-mover advantage in next-generation CETP inhibition
- Strong clinical validation demonstrating LDL reduction and HDL elevation
- Experienced management team with deep biopharmaceutical expertise
Bear Case
1 risk
- Low volatility (beta 0.1).
Growth
Strong growth ahead
Advancement of obicetrapib through clinical development pipeline
Value
Deep value opportunity - significant discount to sector peers
Momentum
Falling
-20.3% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying NAMS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of -$0.52 vs -$0.48 consensus (-7.9% surprise). Revenue of $3.7M vs $2.8M expected (+30.7%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-7.9%
Revenue trend · last 8Q
—
—
—
+740%
-99%
-100%
+2%
-81%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$29.1M
$12.8M
$3.0M
$19.1M
$348.0K
$32.0K
$3.0M
$3.7M
Margins · last 8Q
Gross
0.0%
Operating
0.0%
Profit
0.0%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: BMO Capital · Jul 20, 2026
vs Industry
How NAMS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.